Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Military veterans~* Age between 18 and 55 years old~* Reports of insomnia and nightmares~* Current diagnosis of PTSD~* Currently treated with an SSRI.~* Medications and dosages will remain unchanged for the duration of the study~* Participants will agree to remain in ongoing counseling services they may be receiving prior to study entry.~* Able to read and write English~* Provision of written informed consent~Exclusion Criteria:~* Current, severe, untreated Major Depressive Disorder~* Current history of suicidality requiring hospitalization~* Current history (past 6 months) of substance or alcohol abuse~* Currently actively psychotic or bipolar disorder (past year)~* Resting blood pressure \< 90/60 at the screening physical examination~* Heart rate \> 100 beats/minutes~* Use of an alpha-1 antagonist agent or beta-blocker~* Refusal to follow the safety measures~* Unexpected, untreated, or serious EKG findings~* Medications and/or dosage changed in the past two months~* Unstable medical condition~* Pregnant or breast-feeding women~* Apnea-hypopnea index (AHI) \> 15~* Refusal to provide information relevant to selection criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Medication (Type: ACTIVE_COMPARATOR): Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
- Behavioral (Type: ACTIVE_COMPARATOR): Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES).
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).